GLP-1 medications are a group of prescription drugs used in connection with weight loss. They include brand names like Ozempic, Wegovy, Zepbound, and Saxenda, which are injectable medications designed to reduce a patient’s appetite, increase a feeling of “fullness,” and/or block fat absorption.
Rybelsus is a related medication in pill form that is often used in connection with Type 2 Diabetes but can also lead to weight loss.
A pill version of Ozempic entered the market in 2026. Another pill form medication, orforglipron, developed by Eli Lilly, is expected to also enter the market in 2026. Others are expected to follow.
Insurer coverage for GLP-1 drugs varies significantly, and it could change in the future. That’s because the availability of the drugs is increasing – through Medicare and Medicaid (starting in 2026) and through direct-to-consumer offers through Walmart and Costco. Generic versions of some of the drugs could be available as early as 2027.